EPO and Cognitive impairment: The growth factor erythropoietin (EPO) has been shown to be a promising pharmacological treatment of cognitive impairments across neuropsychiatric disorders including mood disorders (Ehrenreich et al., 2007a, b; Miskowiak et al., 2014a, b).